Trends in Outcomes, Financial Burden, and Mortality for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in the United States from 2002 to 2010

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 14, Issue 1, 2017, Pages 72-79

  Jinjuvadia, Chetna ^a   Jinjuvadia, Raxitkumar ^b   Mandapakala, Chaitanya ^a   Durairajan, Navin ^a   Liangpunsakul, Suthat ^c   Soubani, Ayman O ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

COPD; hospitalization costs; mortality; NIS data

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FEMALE; HOSPITAL ADMISSION; HOSPITAL FINANCE; HOSPITAL MORTALITY; HOSPITALIZATION; HOSPITALIZATION COST; HOUSEHOLD INCOME; HUMAN; ICD-9; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNITED STATES; ACUTE DISEASE; ADULT; AFRICAN AMERICAN; AGE; CAUCASIAN; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; HISPANIC; MIDDLE AGED; MORTALITY; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TRENDS;

ACUTE DISEASE; ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH CARE COSTS; HISPANIC AMERICANS; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MEDICARE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEX FACTORS; UNITED STATES;

EID: 84978522070     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412555.2016.1199669     Document Type: Article

References (12)

1. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013; 5:235–245.
2. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease:a randomised controlled trial. Lancet 2003; 361(9356):449–456.
3. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362(9389):1053–1061.
4. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775–789.
5. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347–365.
6. Healthcare Cost and Utilization Project (HCUP) databases. Agency for HealthcareResearch and Quality. http://www.hcup-us.ahrq.gov/databases.jsp. 2013.
7. Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003; 163(10):1180–1186.
8. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations:impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006; 15(6):346–353.
9. Moore KD, Eyestone K, Coddington DC. The healthcare cost curve can be bent. Healthc Financ Manage 2013; 67(3):78–84.
10. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118(5):1278–1285.
11. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol 2013; 61(12):1259–1267.
12. Holland A. Telehealth reduces hospital admission rates in patients with COPD. J Physiother 2013; 59(2):129.